5 June 2022

Breast Cancer Now has commented on research presented at the American Society of Clinical Oncology (ASCO) which shows trastuzumab deruxtecan (Enhertu) may benefit even more secondary (metastatic) breast cancer patients.

Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:

“With an estimated 35,000 people living with secondary (metastatic) breast cancer in the UK, we urgently need to find new ways to treat this devastating disease. It’s hugely exciting trastuzumab deruxtecan, which is already being used on the NHS to treat some women with HER2 positive secondary breast cancer, may benefit even more breast cancer patients giving them the hope of additional precious time with their loved ones.

“This treatment must now be promptly submitted for licensing, and assessed for use on the NHS, so this different group of eligible women have the chance to benefit from it as soon as possible. Anyone affected by breast cancer can speak to Breast Cancer Now’s expert nurses by calling our free Helpline on 0808 800 6000 for information and support.”